MNG1232
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.571
- ANGIOGENESIS+0.404
- INFLAMMATORY_RESPONSE+0.381
- PANCREAS_BETA_CELLS+0.352
- KRAS_SIGNALING_UP+0.336
- IL2_STAT5_SIGNALING+0.310
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.269
- KRAS_SIGNALING_DN+0.266
- APICAL_SURFACE+0.260
- HYPOXIA+0.259
Top 10 suppressed
- PROTEIN_SECRETION-0.515
- MITOTIC_SPINDLE-0.405
- MYC_TARGETS_V1-0.387
- DNA_REPAIR-0.358
- UNFOLDED_PROTEIN_RESPONSE-0.340
- WNT_BETA_CATENIN_SIGNALING-0.322
- UV_RESPONSE_DN-0.317
- HEME_METABOLISM-0.286
- NOTCH_SIGNALING-0.275
- E2F_TARGETS-0.273
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1489821 | GTEX | — | 0.882 |
| 2 | SRR1332317 | GTEX | — | 0.869 |
| 3 | MNG229 | — | — | 0.864 |
| 4 | MNG173 | — | — | 0.857 |
| 5 | SRR1415832 | GTEX | — | 0.855 |
| 6 | MNG1068 | — | — | 0.848 |
| 7 | MDT-AP-2892 | Med | Medulloblastoma | 0.845 |
| 8 | SRR1316254 | GTEX | — | 0.843 |
| 9 | SRR1445238 | GTEX | — | 0.843 |
| 10 | SRR1334847 | GTEX | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.571 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.404 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.381 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.352 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.336 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.310 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.269 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.266 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| HYPOXIA | 0.259 | Idelalisib | — uncovered |
| COAGULATION | 0.248 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.248 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.245 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.219 | Inavolisib | — uncovered |
| COMPLEMENT | 0.172 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.156 | Inavolisib | — uncovered |
| MYOGENESIS | 0.147 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.133 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.123 | Idelalisib | — uncovered |